FASTS FACTS AND CONCEPTS #74
ORAL OPIOID ORDERS: GOOD AND BAD EXAMPLES
David E Weissman MD

Introduction
This Fast Fact will illustrate poorly written opioid orders and provide preferred alternatives.

Scenario 1: Episodic (non-continuous) moderate-to-severe pain

Bad Example: ‘Oxycodone w/ acetaminophen (Percocet), 1-2 PO q 4-6 hour PRN severe pain, and acetaminophen w/codeine (Tylenol #3) 1-2 PO q4-6 PRN moderate pain.’

Discussion: This order has several problems.

1) The duration of short-acting opioids is typically 3-4 hours - rarely 6 hours. Studies document that when given a range, nurses and doctors are most likely to give the lowest dose at the longest interval, leading to inadequate analgesia.

2) Only one opioids/non-opioid combination should be prescribed at a time: assess for response and change to different product if the first agent does not produce the desired effect.

3) The use of descriptors (‘mild,’ ‘moderate,’ ‘severe’) allows for subjective interpretation of pain severity by the nurse, rather than judging pain severity directly based on patient report. There is a very poor correlation of pain ratings between patients and clinicians.

4) Should both drugs be used, there is risk of exceeding 4 grams/day of acetaminophen.

Preferred order: ‘Oxycodone w/ acetaminophen, 1-2 tabs PO q 4 hours PRN pain.’

Scenario 2: Order for an oral long-acting opioid

Bad Example: ‘Morphine extended-release 60 mg q 6 hours and transdermal fentanyl patch 25 mcg/hour, changed q 72 hours.’

Discussion: This order has two problems. First, none of the oral long-acting products (e.g. MS Contin, OxyContin, Kadian) should be prescribed less than Q8h; Q12 is the recommended starting interval, although many patients need a q8h interval. Second, there is no rationale for using two different long-acting products at the same time. Prescribe only one drug, then dose escalate to desired effect or unacceptable toxicity. Remember to always prescribe a PRN product for breakthrough pain. While the oral long-acting products can be dose escalated every 24 hours, the transdermal fentanyl patch can only be safely dose escalated every 2-3 days. Thus, it is a poor choice for poorly controlled pain.

Preferred order: ‘Morphine extended-release 150 mg q 12 hours.’ (The dose of 150 mg q12 hours is derived from the following equianalgesic relationships: morphine 60 mg q6 hours is 240 mg/day; transdermal fentanyl 25mcg/hr = approximately 60 mg/day of oral morphine. 240 + 60 = 300 mg or 150 mg q12 hours. See Fast Fact #2.)

References


4) Friedman FB. PRN analgesics: controlling the pain or controlling the patient? *RN*. 1983; 43:67-78.


*Fast Facts and Concepts* are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the [Palliative Care Network of Wisconsin](http://www.pcnnow.org); the authors of each individual *Fast Fact* are solely responsible for that *Fast Fact's* content. The full set of *Fast Facts* are available at [Palliative Care Network of Wisconsin](http://www.pcnnow.org) with contact information, and how to reference *Fast Facts.*

**Copyright:** All *Fast Facts and Concepts* are published under a Creative Commons Attribution-NonCommerical 4.0 International Copyright ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)). *Fast Facts* can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a *Fast Fact*, let us know!

**Disclaimer:** *Fast Facts and Concepts* provide educational information for health care professionals. This information is not medical advice. *Fast Facts* are not continually updated, and new safety information may emerge after a *Fast Fact* is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some *Fast Facts* cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.